Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of YC-6 (安脑三醇注射液) for prevention of radiation-induced brain injury
CTR20263251Phase 2Active
- Sponsor
- Guangzhou Cellprotek Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of androtriol in radiation-induced encephalopathy (RIE), sponsored by Guangzhou Cellprotek Pharmaceutical Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
androtriol
03
Conditions
radiation-induced encephalopathy (RIE)
Beyond the preview
Go deeper on CTR20263251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263251.